Stifel analyst Rick Wise lowered the firm’s price target on Profound Medical (PROF) to $10 from $12 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PROF:
- Profound Medical Schedules First-Quarter 2026 Earnings Release
- Profound Medical to Present Business Update at Conference
- Profound Medical Showcases TULSA-PRO at Key Radiology Meeting
- Profound Medical Marks Key TULSA Milestone as Texas Prostate Tops 100 Procedures
- Profound Medical Trial Shows TULSA Improves Prostate Cancer Outcomes